Literature DB >> 9336307

The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data.

R S Obach1, J G Baxter, T E Liston, B M Silber, B C Jones, F MacIntyre, D J Rance, P Wastall.   

Abstract

We describe a comprehensive retrospective analysis in which the abilities of several methods by which human pharmacokinetic parameters are predicted from preclinical pharmacokinetic data and/or in vitro metabolism data were assessed. The prediction methods examined included both methods from the scientific literature as well as some described in this report for the first time. Four methods were examined for their ability to predict human volume of distribution. Three were highly predictive, yielding, on average, predictions that were within 60% to 90% of actual values. Twelve methods were assessed for their utility in predicting clearance. The most successful allometric scaling method yielded clearance predictions that were, on average, within 80% of actual values. The best methods in which in vitro metabolism data from human liver microsomes were scaled to in vivo clearance values yielded predicted clearance values that were, on average, within 70% to 80% of actual values. Human t1/2 was predicted by combining predictions of human volume of distribution and clearance. The best t1/2 prediction methods successfully assigned compounds to appropriate dosing regimen categories (e.g., once daily, twice daily and so forth) 70% to 80% of the time. In addition, correlations between human t1/2 and t1/2 values from preclinical species were also generally successful (72-87%) when used to predict human dosing regimens. In summary, this retrospective analysis has identified several approaches by which human pharmacokinetic data can be predicted from preclinical data. Such approaches should find utility in the drug discovery and development processes in the identification and selection of compounds that will possess appropriate pharmacokinetic characteristics in humans for progression to clinical trials.

Entities:  

Mesh:

Year:  1997        PMID: 9336307

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  172 in total

Review 1.  Prediction of hepatic metabolic clearance: comparison and assessment of prediction models.

Authors:  J Zuegge; G Schneider; P Coassolo; T Lavé
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

2.  Comparison of in vitro hepatic models for the prediction of metabolic interaction between simvastatin and naringenin.

Authors:  N Le Goff; J C Koffel; S Vandenschrieck; L Jung; G Ubeaud
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2002 Oct-Dec       Impact factor: 2.441

3.  The use of in vitro metabolic stability for rapid selection of compounds in early discovery based on their expected hepatic extraction ratios.

Authors:  Yan Yi Lau; Gopal Krishna; Nathan P Yumibe; Diane E Grotz; Elpida Sapidou; Laura Norton; Inhou Chu; Cliff Chen; A D Soares; Chin-Chung Lin
Journal:  Pharm Res       Date:  2002-11       Impact factor: 4.200

Review 4.  Prediction of hepatic metabolic clearance based on interspecies allometric scaling techniques and in vitro-in vivo correlations.

Authors:  T Lavé; P Coassolo; B Reigner
Journal:  Clin Pharmacokinet       Date:  1999-03       Impact factor: 6.447

5.  Optimization of 2,4-diarylanilines as non-nucleoside HIV-1 reverse transcriptase inhibitors.

Authors:  Lian-Qi Sun; Bingjie Qin; Li Huang; Keduo Qian; Chin-Ho Chen; Kuo-Hsiung Lee; Lan Xie
Journal:  Bioorg Med Chem Lett       Date:  2012-02-24       Impact factor: 2.823

Review 6.  Applications of human pharmacokinetic prediction in first-in-human dose estimation.

Authors:  Peng Zou; Yanke Yu; Nan Zheng; Yongsheng Yang; Hayley J Paholak; Lawrence X Yu; Duxin Sun
Journal:  AAPS J       Date:  2012-03-10       Impact factor: 4.009

7.  In silico prediction of aqueous solubility, human plasma protein binding and volume of distribution of compounds from calculated pKa and AlogP98 values.

Authors:  Mario Lobell; Vinothini Sivarajah
Journal:  Mol Divers       Date:  2003       Impact factor: 2.943

Review 8.  Whole body pharmacokinetic models.

Authors:  Ivan Nestorov
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

9.  Inter-individual variability in levels of human microsomal protein and hepatocellularity per gram of liver.

Authors:  Z E Wilson; A Rostami-Hodjegan; J L Burn; A Tooley; J Boyle; S W Ellis; G T Tucker
Journal:  Br J Clin Pharmacol       Date:  2003-10       Impact factor: 4.335

10.  Comparison of the use of liver models for predicting drug clearance using in vitro kinetic data from hepatic microsomes and isolated hepatocytes.

Authors:  Kiyomi Ito; J Brian Houston
Journal:  Pharm Res       Date:  2004-05       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.